Candriam S.C.A. Has $5.76 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Candriam S.C.A. boosted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 135.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 247,591 shares of the company’s stock after buying an additional 142,591 shares during the period. Candriam S.C.A. owned approximately 0.48% of Spyre Therapeutics worth $5,764,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of SYRE. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Spyre Therapeutics during the fourth quarter valued at about $46,000. Arizona State Retirement System raised its holdings in shares of Spyre Therapeutics by 38.4% during the fourth quarter. Arizona State Retirement System now owns 10,115 shares of the company’s stock valued at $235,000 after purchasing an additional 2,805 shares during the period. Rhumbline Advisers raised its holdings in shares of Spyre Therapeutics by 6.9% during the fourth quarter. Rhumbline Advisers now owns 57,657 shares of the company’s stock valued at $1,342,000 after purchasing an additional 3,722 shares during the period. Quest Partners LLC raised its holdings in shares of Spyre Therapeutics by 271.2% during the third quarter. Quest Partners LLC now owns 5,654 shares of the company’s stock valued at $166,000 after purchasing an additional 4,131 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Spyre Therapeutics by 15.0% during the third quarter. The Manufacturers Life Insurance Company now owns 43,460 shares of the company’s stock valued at $1,278,000 after purchasing an additional 5,678 shares during the period. Institutional investors and hedge funds own 80.39% of the company’s stock.

Spyre Therapeutics Price Performance

NASDAQ:SYRE opened at $19.49 on Friday. The firm has a 50-day moving average of $21.91 and a 200-day moving average of $26.55. The company has a market cap of $1.17 billion, a PE ratio of -2.61 and a beta of 2.98. Spyre Therapeutics, Inc. has a one year low of $17.24 and a one year high of $47.97.

Spyre Therapeutics (NASDAQ:SYRE) last posted its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.08. On average, equities research analysts expect that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on SYRE shares. Robert W. Baird upped their price objective on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, Wedbush reiterated an “outperform” rating and set a $65.00 price objective on shares of Spyre Therapeutics in a report on Monday, January 13th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $54.83.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).